Predicting prognosis of rectal cancer patients with total mesorectal excision using molecular markers

Table 1 Summary of clinicopathological data (n = 259)

Characteristics	Cases (%)
Gender
Male	146 (56.4)
Female	113 (43.6)
Age (yr)
Range	18-80
Median	56
Tumor location
> 10 cm1	62 (23.9)
7-10 cm1	115 (44.4)
5-7 cm1	82 (31.7)
Mean Max diameter (cm)	4.68
Pathology
Adenocarcinoma	236 (91.1)
Mucinous aden3	18 (6.9)
Signet ring ca3	5 (2)
T stage
T1	18 (7.0)
T2	83 (32.0)
T3	85 (32.8)
T4	73 (28.2)
N stage
N0	147 (56.8)
N1	62 (23.9)
N2	50 (19.3)
TNM stage (AJCC/UICC)
I	80 (30.9)
II	67 (25.9)
III	112 (43.2)
Lymphovascular invasion
Yes	33 (12.7)
No	226 (87.3)
Neural invasion
Yes	21 (8.1)
No	238 (91.9)
Pre-operative CEA2
Positive	48 (18.5)
Negative	211 (81.5)
Adjuvant therapy
S	167 (64.5)
S + C	92 (35.5)

¹Distance of the tumor from anal verge;

²In our hospital lab, CEA > 10 μg/L is considered positive. S: surgery; C: chemotherapy.